Bioliberty Raises $10.2 Million in Series A Funding

Bioliberty, an Edinburgh-based medtech company focused on engineering the future of physical and occupational therapy, has successfully raised $10.2 million in a Series A funding round. This round was led by the Scottish National Investment Bank, with participation from Archangels, Eos Advisory, Old College Capital, Hanna Capital SEZC, and new investor Conduit Connect.

Company Background and Leadership

Founded in 2020, Bioliberty was co-founded by Ross O'Hanlon, who serves as the Chief Technology Officer, and Shea Quinn, the Chief Operating Officer. The company is at the forefront of developing innovative solutions like the Lifehub platform and the Lifeglov, a soft robotic glove designed to assist in physical rehabilitation.

Purpose of the Funding

The newly acquired funds are earmarked for several strategic initiatives:

  • Development and Commercialization: Bioliberty plans to advance the development and U.S. commercialization of its Lifehub platform, which is aimed at improving post-acute care delivery through enhanced functional intelligence capabilities.
  • Expansion of Features: The funding will support the expansion of computer vision and care coordination features within the Lifehub platform, as well as the rollout of Lifehub Home. This extension aims to bring therapy and monitoring into patients’ homes, thus broadening the platform’s reach and effectiveness.

Technological Innovations

Bioliberty's Lifehub platform, which launched in 2025, utilizes artificial intelligence and robotics to monitor recovery and enhance therapy in post-acute settings. It provides clinicians with crucial data to track patient recovery, identify high-risk patients, and make informed, data-driven care decisions. The platform is already gaining traction among major U.S. rehabilitation providers and has been involved in partnerships with institutions like Mount Sinai and the U.S. Department of Veterans Affairs.

Strategic Board Appointments

As part of this funding round, Russell Bailey, President of Lifepoint Rehabilitation, and Dana Prommel Strauss, Lead Director of Public Policy and Government Affairs at CVS Health, have joined Bioliberty’s Board of Directors. Their expertise is expected to further strengthen the company's strategy and policy alignment in the healthcare sector.

Bioliberty continues to innovate in the medtech space, focusing on improving patient outcomes through intelligent therapy solutions. With this latest funding, the company is well-positioned to expand its capabilities and impact in the post-acute care market.